Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Li

Showing results (91-100 of 139) with videos related to

Pageof 14
Sort By:
Physica Medica : PM : an International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (AIFB)|September 3, 2025
Virtual radiotherapy plan quality education: Perspectives from a global settingCaroline M Colbert, Emily Kruse, Dustin Jacqmin, et al.
Lung Cancer (Amsterdam, Netherlands)|January 7, 2026
Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitorsGeoffrey Liu, Devin Abrahami, Priya Ramachandran, et al.
Lung Cancer (Amsterdam, Netherlands)|February 23, 2025
Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]Jessica R Bauman, Geoffrey Liu, Isabel Preeshagul, et al.
The Oncologist|July 15, 2025
Noninterventional retrospective study of standard-of-care systemic treatment patterns and outcomes in US patients with advanced urothelial carcinomaHelen H Moon, Melissa Kirker, Anup Abraham, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2024
Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancerJessica R Bauman, Geoffrey Liu, Isabel Preeshagul, et al.
The Journal of Urology|December 20, 2015
A Model to Optimize Followup Care and Reduce Hospital Readmissions after Radical CystectomyNaveen Krishnan, Xiang Liu, Mariel S Lavieri, et al.
Lung Cancer (Amsterdam, Netherlands)|November 2, 2024
Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]Jessica R Bauman, Geoffrey Liu, Isabel Preeshagul, et al.
Breast (Edinburgh, Scotland)|April 8, 2026
Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2- metastatic breast cancer in US routine clinical practiceHope S Rugo, Adam Brufsky, Rachel M Layman, et al.
NPJ Breast Cancer|October 11, 2022
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancerHope S Rugo, Adam Brufsky, Xianchen Liu, et al.
Advances in Radiation Oncology|January 5, 2026
Lessons Learned From an Epic Transformation of a Radiation Oncology Department in Guatemala: Keys to SuccessEdgar Ruiz, Hiram A Gay, Milton Ixquiac, et al.
Pageof 14

Showing results (91-100 of 139) with videos related to

Sort By:
Pageof 14
Physica Medica : PM : an International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (AIFB)|September 3, 2025
Virtual radiotherapy plan quality education: Perspectives from a global settingCaroline M Colbert, Emily Kruse, Dustin Jacqmin, et al.
Lung Cancer (Amsterdam, Netherlands)|January 7, 2026
Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitorsGeoffrey Liu, Devin Abrahami, Priya Ramachandran, et al.
Lung Cancer (Amsterdam, Netherlands)|February 23, 2025
Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]Jessica R Bauman, Geoffrey Liu, Isabel Preeshagul, et al.
The Oncologist|July 15, 2025
Noninterventional retrospective study of standard-of-care systemic treatment patterns and outcomes in US patients with advanced urothelial carcinomaHelen H Moon, Melissa Kirker, Anup Abraham, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2024
Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancerJessica R Bauman, Geoffrey Liu, Isabel Preeshagul, et al.
The Journal of Urology|December 20, 2015
A Model to Optimize Followup Care and Reduce Hospital Readmissions after Radical CystectomyNaveen Krishnan, Xiang Liu, Mariel S Lavieri, et al.
Lung Cancer (Amsterdam, Netherlands)|November 2, 2024
Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]Jessica R Bauman, Geoffrey Liu, Isabel Preeshagul, et al.
Breast (Edinburgh, Scotland)|April 8, 2026
Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2- metastatic breast cancer in US routine clinical practiceHope S Rugo, Adam Brufsky, Rachel M Layman, et al.
NPJ Breast Cancer|October 11, 2022
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancerHope S Rugo, Adam Brufsky, Xianchen Liu, et al.
Advances in Radiation Oncology|January 5, 2026
Lessons Learned From an Epic Transformation of a Radiation Oncology Department in Guatemala: Keys to SuccessEdgar Ruiz, Hiram A Gay, Milton Ixquiac, et al.
Pageof 14